If you have been reading about LC-MS/MS and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-12-28. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
These drugs are expected to restore a normal libido in patients. Targeting acquired and generalized hypoactive sexual desire disorder (HSDD), improvement in sexual desire, and alleviation of psychological stress are to relieve the correlated symptoms. However, the treatments cannot cope with medically or psychiatrically related conditions, nor the effects from other medications.
=== Czech === Traditionally, the word nejneobhospodařovávatelnějšími ("of the least cultivable", 28 letters) is considered as the longest Czech word, but there are some longer artificial words. Most of them are compound adjectives in dative, instrumental or other grammatical case and derived from the iterative or frequentative verbal form or the ability adjective form (like "-able").
=== Convenience, automation === In vitro methods can be miniaturized and automated, yielding high-throughput screening methods for testing molecules in pharmacology or toxicology. In toxicology, U.S. agencies such as the EPA use high-throughput in vitro screening to test large numbers of chemicals and reduce the need for animal-based toxicity tests.
Richards echoed this sentiment, writing in a 2007 review, "[psychedelic] mushroom use may constitute one technology for evoking revelatory experiences that are similar, if not identical, to those that occur through so-called spontaneous alterations of brain chemistry." A group of researchers from Johns Hopkins School of Medicine led by Roland Griffiths conducted a study to assess the immediate and long-term psychological effects of the psilocybin experience, using a modified version of the mystical experience questionnaire and a rigorous double-blind procedure. When asked in an interview about the similarity of his work to Leary's, Griffiths explained the difference: "We are conducting rigorous, systematic research with psilocybin under carefully monitored conditions, a route which Dr. Leary abandoned in the early 1960s." Experts have praised the National Institute of Drug Abuse-funded study, published in 2006, for the soundness of its experimental design. In the experiment, 36 volunteers with no experience with hallucinogens were given psilocybin and methylphenidate (Ritalin) in separate sessions; the methylphenidate sessions served as a control and psychoactive placebo. The degree of mystical experience was measured using a questionnaire developed by Ralph W. Hood; 61% of subjects reported a "complete mystical experience" after their psilocybin session, while only 13% reported such an outcome after their experience with methylphenidate.
Sources: en.wikipedia.org
==== Nanowire compositions ==== Scientists have devised a large number of nanowire compositions with controlled length, diameter, doping, and surface structure by using vapor and solution phase strategies. These oriented single crystals are being used in semiconductor nanowire devices such as diodes, transistors, logic circuits, lasers, and sensors. Since nanowires have a one-dimensional structure, meaning a large surface-to-volume ratio, the diffusion resistance decreases. In addition, their efficiency in electron transport which is due to the quantum confinement effect, makes their electrical properties be influenced by minor perturbation. Therefore, the use of these nanowires in nanosensor elements increases the sensitivity in electrode response. As mentioned above, the one-dimensionality and chemical flexibility of the semiconductor nanowires make them applicable in nanolasers. Peidong Yang and his co-workers have done some research on the room-temperature ultraviolet nanowires used in nanolasers. They have concluded that using short wavelength nanolasers has applications in different fields such as optical computing, information storage, and microanalysis.
Autofluorescence is the natural fluorescence of biological structures (autofluorophores) such as mitochondria and lysosomes, in contrast to fluorescence originating from artificially added fluorescent markers (fluorophores). The most commonly observed autofluorescencing molecules are NADPH and flavins; the extracellular matrix can also contribute to autofluorescence because of the intrinsic properties of collagen and elastin. Generally, proteins containing an increased amount of the amino acids tryptophan, tyrosine, and phenylalanine show some degree of autofluorescence. Autofluorescence also occurs in non-biological materials found in many papers and textiles. Autofluorescence from U.S. paper money has been demonstrated as a means for discerning counterfeit currency from authentic currency.
== External links == GeneReviews/NCBI/NIH/UW entry on von Willebrand Factor Deficiency. Includes: Type 1 von Willebrand Disease, Type 2A von Willebrand Disease, Type 2B von Willebrand Disease, Type 2M von Willebrand Disease, Type 2N von Willebrand Disease, Type 3 von Willebrand Disease Overview of all the structural information available in the PDB for UniProt: P04275 (von Willebrand factor) at the PDBe-KB.
== External links == GeneReviews/NCBI/NIH/UW entry on Cystinosis Human CTNS genome location and CTNS gene details page in the UCSC Genome Browser. Genetics Home Reference page on CTNS. Genetic Testing Registry.
The approval was based on comparisons of extensive structural and functional product characterization, animal data, human pharmacokinetic, clinical immunogenicity, and other clinical data demonstrating that Herzuma is biosimilar to US Herceptin. Herzuma has been approved as a biosimilar, not as an interchangeable product. Kanjinti was authorized for medical use in the European Union in May 2018. Trazimera was authorized for medical use in the European Union in July 2018. Ogivri was approved for medical use in Canada in May 2019. Trazimera was approved for medical use in Canada in August 2019. Herzuma was approved for medical use in Canada in September 2019. Kanjinti was approved for medical use in Canada in February 2020. Zercepac was authorized for medical use in the European Union in July 2020. Trastucip and Tuzucip were approved for medical use in Australia in July 2022. In September 2023, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Herwenda, intended for the treatment of HER2-positive breast and gastric cancer. The applicant for this medicinal product is Sandoz GmbH. Herwenda was authorized for medical use in the European Union in November 2023. Trastuzumab-strf (Hercessi) was approved for medical use in the United States in April 2024.
Sources: en.wikipedia.org
Specialty pharmacies supply high-cost injectable, oral, infused, or inhaled medications that are used for chronic and complex disease states such as cancer, hepatitis, and rheumatoid arthritis. Unlike a traditional community pharmacy where prescriptions for any common medication can be brought in and filled, specialty pharmacies carry novel medications that need to be properly stored, administered, carefully monitored, and clinically managed. In addition to supplying these drugs, specialty pharmacies also provide lab monitoring, adherence counseling, and assist patients with cost-containment strategies needed to obtain their expensive specialty drugs. In the US, it is currently the fastest-growing sector of the pharmaceutical industry with 19 of 28 newly Food and Drug Administration (FDA) approved medications in 2013 being specialty drugs. Due to the demand for clinicians who can properly manage these specific patient populations, the Specialty Pharmacy Certification Board has developed a new certification exam to certify specialty pharmacists. Along with the 100 questions computerized multiple-choice exam, pharmacists must also complete 3,000 hours of specialty pharmacy practice within the past three years as well as 30 hours of specialty pharmacist continuing education within the past two years.
=== Sweden === In Sweden, a medical license is required before commencing specialty training. Those graduating from Swedish medical schools are first required to do a rotational internship of about 1.5 to 2 years in various specialties before attaining a medical license. The specialist training lasts 5 years.
=== Pharmacodynamics === Tiagabine acts a selective GABA transporter 1 (GAT-1) blocker and hence as a GABA reuptake inhibitor (GRI). The GAT-1 is one of at least four distinct GABA transporters (GATs), with the GAT-1 being the predominant subtype in the brain, accounting for 85% of GATs in this part of the body, and thought to be responsible for most γ-aminobutyric acid (GABA) reuptake in synapses. The drug has more than 1,000-fold selectivity for the GAT-1 over the GABA transporter 2 (GAT-2), GABA transporter 3 (GAT-3), and betaine/GABA transporter (BGT-1; GAT-4). It also shows no significant affinity for GABA receptors or numerous other targets. In addition, it does not affect key cardiac ion channels. Through GAT-1 blockade, tiagabine increases levels of GABA, the major inhibitory neurotransmitter in the central nervous system, and consequently increases GABA receptor activation and GABAergic signaling, including of both GABAA and GABAB receptors. The drug has been found to increase GABAergic signaling in the hippocampus, globus pallidus, ventral pallidum, and substantia nigra in animals. It produces anticonvulsant, neuroprotective, hypnotic, analgesic, and anxiolytic-like effects in animals. In rodent drug discrimination tests, tiagabine partially substituted for muscimol and diazepam but did not substitute for gaboxadol, phenobarbitol, or zolpidem. When tiagabine was used as the training drug however, gaboxadol near-fully substituted for tiagabine. Similarly, indiplon partially substituted for tiagabine.
During this period, the first CEO also served in an individual capacity as Chief Advisor to the Department of Agriculture and Farmers Welfare on supply chain and post-harvest management in India. NCDD was involved in government discussions on Agri-logistics and cold chain development. NCCD think tank has participation from various private & government stakeholders ranging from Educational & Research Institutions, Regulatory authorities, Trade bodies, individual Companies involved as users or providers of cold-chain, farmer Groups and Associations as well as Individuals as Associate members. NCCD comprises members from the cold-chain stakeholders community and administered by its office secretariat staff. Each such member group also elects representation on the governing council, enabling NCCD to reflect inclusive governance and emulate a public-private partnership model. As of February 2020, Dr BNS Murthy (a government officer and the Horticulture Commissioner of India), has been nominated to the role of Chief Executive Officer.
As of December 2019, there is no effective pharmacotherapy for amphetamine addiction. Reviews from 2015 and 2016 indicated that TAAR1-selective agonists have significant therapeutic potential as a treatment for psychostimulant addictions; however, as of February 2016, the only compounds which are known to function as TAAR1-selective agonists are experimental drugs. Amphetamine addiction is largely mediated through increased activation of dopamine receptors and co-localized NMDA receptors in the nucleus accumbens; magnesium ions inhibit NMDA receptors by blocking the receptor calcium channel. One review suggested that, based upon animal testing, pathological (addiction-inducing) psychostimulant use significantly reduces the level of intracellular magnesium throughout the brain. Supplemental magnesium treatment has been shown to reduce amphetamine self-administration (i.e., doses given to oneself) in humans, but it is not an effective monotherapy for amphetamine addiction. A systematic review and meta-analysis from 2019 assessed the efficacy of 17 different pharmacotherapies used in randomized controlled trials (RCTs) for amphetamine and methamphetamine addiction; it found only low-strength evidence that methylphenidate might reduce amphetamine or methamphetamine self-administration.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.